Möchten Sie immer auf dem neuesten Stand bleiben?

REGULATED INFORMATION GHENT, Belgium, May 13, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007...

REGULATED INFORMATION Reported positive top line results from first-in-infant Phase I/IIa study of the inhaled anti-RSV Nanobody® (ALX-0171) Clinical product pipeline expanded with...

Primary endpoint of safety and tolerability met Anti-viral effect demonstrated and encouraging initial indication of therapeutic effect Results support advancing the programme into a...

Second Nanobody® targeting a G-protein-coupled receptor (GPCR) enters clinical development Further positive validation of Ablynx's Nanobody platform and its ability to address complex...

REGULATED INFORMATION GHENT, Belgium, April 22, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007...

GHENT, Belgium and INGELHEIM, Germany, April 21, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] and Boehringer Ingelheim today announced the initiation of a Phase I study to...

REGULATED INFORMATION GHENT, Belgium, March 22, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007...

REGULATED INFORMATION GHENT, Belgium, March 14, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May...

REGULATED INFORMATION GHENT, Belgium, March 7, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May...

REGULATED INFORMATION Key value drivers in pre-clinical and clinical development are progressing well Conference call and webcast today at 4pm CET/10am EST GHENT, Belgium, Feb. 25, 2016...